Investigational drug for treatment of Triple-Negative Breast Cancer

Trial ID:
IRB-24-8422
Mohammed Ali Jaloudi, MD

Inclusion Criteria

Patients must:

  • Be men or women 18 years of age or older
    Have centrally confirmed Triple-Negative Breast Cancer
    Have had a non pathologic complete response at surgery
    Have had neoadjuvant chemotherapy

Exclusion Criteria

Patients must not:

  • Be pregnant or breastfeeding
    Have the BRCA mutation
    Have peripheral neuropathy
    Have history of severe dry eye syndrome
    Have active inflammatory bowel disease requiring immunosuppressive medication
    Have uncontrolled, significant cardiovascular disease
    Received prior treatment with a TROP2-directed ADC

Additional Info

All treatments and physician visits during the study will take place at Scripps Clinic Torrey Pines (Geisel Pavilion)

For more information search NCT06393374 at www.clinicaltrials.gov

Contact Info:

  • Clinical Research Services
  • crsleadership@scrippshealth.org